E
MSKCC Trial Suspensions

The real story behind Juno’s CAR T cell therapy suspensions

This weekend at AACR a controversy emerged on the safety of Juno's CAR T cell therapy.

April 6, 2014
E
Screenshot 2014-04-02 13.29.39

Innate immunotherapy – is it ready for prime time in cancer research?

A review of innate immunotherapies including CD47, KIR, MICA and anti-glucan data at AACR in San Diego.

April 2, 2014
E
JNK_Pathway

Novel targets and approaches in triple negative breast cancer

What are the new targets and drug combinations that are emerging in triple negative breast cancer (TNBC)? find out more about the promising developments in this field.

April 1, 2014
E
Clovis Oncology CO-1686 ELCC 2014

AACR 2014 Preview: Novel targets and approaches

Review of some interesting cancer pipeline drugs at AACR 2014 including TKIs and ADC therapies.

March 27, 2014
E
Source: Nature

Do ESR1 mutations drive endocrine resistance during the progression of ER+ breast cancer?

Today brings the launch of our series on the AACR annual meeting Previews.  A variety of different…

March 25, 2014
E
ISPY2 trial plan

On neratinib in neoadjuvant breast cancer

Puma Biotech are expected to present the neoadjuvant data from ISPY2 for their pan HER inhibitor, neratinib, so what's the deal?

March 14, 2014
E
south pointe

MBCC: Will NGS change the way we treat metastatic breast cancer?

Dr Debu Tripathy presented one of the highlights of the MBCC conference - how we can use genomics to improve clinical trials in TNBC and MBC.

March 13, 2014
E
MBCC14

MBCC: Changing the way we approach advanced breast cancer

Can therapy for advanced breast cancer be individualized using proteomics and genomics data?

March 12, 2014
E
Source: James Kochendefer, NCI

Will CAR T cells give new therapies for NHL and CLL a run for their money?

Much has been written about CAR T cells in B cell leukemias, but what about B cell lymphomas? Kite and the NCI had the honour of being the first to present data from ASH on their therapy in refractory DLBCL lymphomas

March 6, 2014
E
Logo of American Society of Hematology

ASH 2013: Is carfilzomib associated with increased cardiovascular events?

There has been much debate about the cardiovascular risks associated with proteasome inhibitors in multiple myeloma, but what does the data show? A synopsis of the ASH 2013 data and what we can learn in the future...

February 14, 2014
E
Bertrand Tombal ASCO GU 2013

ASCO GU 2014: Will there be a market for Medivation’s enzalutamide in M0 prostate cancer?

The new race to market in advanced prostate cancer is in the M0 asymptomatic space. Several AR antagonists are competing to run trials here but will they lead to men living longer or not?

February 10, 2014
E
Anti-CTLA-4 ipilimumab

Update on immuno-oncology and biomarkers of response

ASCO GU saw an update on the ipilimumab study in post chemotherapy CRPC. New biomarker data published this week in melanoma may be potentially useful in prostate and other tumour types.

February 5, 2014
E
Screenshot 2014-02-04 15.14.55

ASCO GU 2014 Optimal targeting of anti PD-1 and PD-L1 therapies in renal cancer

Update on progress with anti-PD1 and PD-L1 immunotherapies in renal cell cancer. Where is the field going in this space?

February 4, 2014
E
Andrew Armstrong ASCO GU Title Slide

ASCO GU 2014 Beyond Enzalutamide and Abiraterone – What’s Next?

Cross resistance between enzalutamide and abiraterone means that new prostate cancer drugs and targets are needed.

January 31, 2014
E
San Francisco Coit Tower

ASCO GU 2014: Will Galeterone make it to market in Prostate Cancer?

At ASCO GU 2014 Tokai Pharmaceuticals report data for the ARMOR2 trial with reformulated galeterone (TOK-001) in men with prostate cancer. Is this drug likely to make it to market?

January 30, 2014
E
GU14 MDVN PREVAIL

ASCO GU Interview with Dr Tom Beer on Medivation PREVAIL trial data

Enzalutamide significantly decreases the risk of death and delays progression in the PREVAIL trial

January 28, 2014
E
San Francisco Embarcadero

ASCO GU 2014: Why does the Medivation PREVAIL trial matter?

At ASCO GU this week, the clinical data will be presented for the Medivation/Astellas PREVAIL phase III clinical trial of enzalutamide (Xtandi) in men with advanced prostate cancer prior to chemotherapy. The results of this trial not only have important commercial implications for Medivation/Astellas but for competitors in the prostate cancer market.

January 27, 2014
E
Source: Roche

Update on anti-PD-L1 cancer immunotherapy

Roche Genentech are developing their anti-PD-L1 as both monotherapy and also in combination with targeted therapies in lung, melanoma, renal and colon cancers. How is the early development progressing?

January 22, 2014
E
Title Slide ASCO GI Keynote

ASCO GI Keynote: The future of Immunotherapy is Combinations

“We are at beginning of a REVOLUTION in immunotherapy,” said Elizabeth M. Jaffee, MD at the start of American Society of Clinical Oncology GastroIntestinal (ASCO GI) symposium keynote lecture on Immunologic Treatments for GI Cancers.

January 21, 2014
E
Clovis Oncology JPM 2014

Update on CO-1686 and AZD9291 race to market in T790M NSCLC

Update from JP Morgan Healthcare 2014 on Clovis Oncology and AstraZeneca race to market with new drugs for treatment of T790M positive non-small cell lung cancer.

January 15, 2014
E
AGIOS ASH Slide

Can Agios score a winner with their anti-cancer metabolism molecules?

Agios Pharmaceuticals is focused on developing new therapies that target mutations in cancer metabolism, including IDH 1 and 2 for AML and Glioblastoma. Will they be successful despite the huge complexity involved in the underlying processes?

January 13, 2014
E
CAR T Cells

ASH 2013 Stunning ALL data with Novartis CTL019 CAR Therapy

UPenn and CHOP are using genetically modified chimeric antigen receptor (CAR) T cells to treat patients with B cell cancers such as ALL, B cell NHL, CLL and other B cell malignancies. At ASH, the impressive data from adult and pediatric ALL was presented. This post includes insights on this approach and an interview with Dr Stephan Grupp on the pediatric data.

January 9, 2014
E
Foundation Medicine ASH 2013

Insights on Foundation Medicine and how molecular testing will transform cancer research

Increasingly, we are seeing the evolution of diagnostic tests in cancer research. Foundation Medicine are using their gene sequencing platform to identify actionable mutations and assist oncologists make better treatment decisions for their patients.

January 8, 2014
E
Screen Shot 2014-01-07 at 11.22.26 AM

New Immunotherapy data at IASLC Lung Cancer Meeting

Immunotherapy continues to be a hot topic in oncology with anti-PD-1 and other new approaches being discussed at the AACR-IASLC meeting in San Diego

January 7, 2014
E
EXEL Share Price Jan 6 2014

Will Exelixis Cabozantinib COMET-1 prostate cancer trial be positive?

The share price of Exelixis ($EXEL) is starting a run-up (after months in the doldrums) in advance of anticipated results from the COMET-1 phase 3 trial in metastatic castrate resistant prostate cancer (mCRPC) for cabozantinib (Cometriq, formerly XL184). Cabozantinib has been shown to significantly improve bone scans and decrease pain, but will it show an improvement in OS?

January 6, 2014
E
San Francisco ASCO GI Cancer Symposium 2013

ASCO GI 2014 Preview: Pancreatic and Gastric Cancer

Preview of some of the key data being presented at ASCO GI in San Francisco this month.

January 3, 2014
E
San Francisco Golden Gate Bridge

ASCO GU 2014 Prostate Cancer Preview #GU14

ASCO GU symposium takes place at the San Francisco Marriott Marquis from Jan 20 – February 1, 2014. This preview discusses data to be presented on enzalutamide (Xtandi), abiraterone (Zytiga), ODM-201, ARN-509, ipilimumab (Yervoy).

December 30, 2013
E
ASH 2013 Poster Hall

ASH 2013 – gems from the poster halls

There are some 5,000 abstarcts at ASH, many of them posters - what were the interesting nuggets this year?

December 18, 2013
E
BCR Signaling

ASH 2013: New BTK Inhibitor ONO-4059 shows early promise in CLL – is it a future competitor to ibrutinib?

BTK inhibition in the B cell receptor (BCR) pathway has been an exciting area of development over the last couple of years. What do the new competitors entering this space look like?

December 17, 2013
E
ASH

Winners and Losers in CLL at American Society of Hematology

There was a wealth of new data in CLL at ASH but which companies or drugs were the winners and losers in New Orleans? Find out...

December 16, 2013
E
Renier Brentjens ASH 2013 Disclosure

Juno Therapeutics takes on Novartis and seeks to revolutionize the treatment of blood cancers – an interview with Renier Brentjens

Juno Therapeutics is a start-up company with a mission to revolutionize the treatment of blood cancers through the use of chimeric antigen receptor (CAR) modified T cell therapy. The company recently launched with $120 million of series A funding. One of the scientific founders is Renier Brentjens MD, PhD, the Director of Cell Therapeutics at the Memorial Sloan-Kettering Cancer Center in NYC. He kindly gave an interview while at the ASH annual meeting in New Orleans.

December 13, 2013
E
The Alamo San Antonio

AbbVie’s PARP inhibitor veliparib is highly active in triple negative breast cancer

The first readout from the I-SPY2 neoadjuvant breast cancer trial comes from the veliparib (PARP) arm.

December 13, 2013
E
KIR Occupancy by IPH2101

Will anti-KIR immunotherapy make an impact in hematologic malignancies?

Immuno-oncology is a hot topic at the moment and many new targets are emerging that may be useful in combination. This post discusses Innate Pharma's anti-KIR program in hematologic malignancies.

December 12, 2013
E
San Antonio River Walk

What to watch for at San Antonio Breast Cancer Symposium

A preview of some of the landmark trial data emerging from the 2013 San Antonio Breast Cancer Symposium

December 11, 2013
E
ASH 2013 Annual Meeting

ASH 2013 Novel Treatments for CLL – notes from the road

One of the most interesting oral sessions at ASH 2013 took place on the last day and featured data on novel treatments for CLL. Data was presented on ABT-199, dinaciclib and the CAR-modified T-cell therapies in development by Novartis & Juno Therapeutics.

December 11, 2013
E
ASH 2013 Lymphoma Session

ASH 2013 Novel Agents in Lymphoma – notes from the road

At ASH 2013 data on novel agents for the treatment of lymphoma was presented. This post discusses data for idelalisib in iNHL, SAR245409 in R/R Follicular Lymphoma and BAY-BAY 80-6946 (copanlisib).

December 9, 2013
E
Prof John Seymour ASH 2013

ASH 2013 ABT-199 CLL TLS Death blamed on Failure to Follow Protocol

In the ASH 2013 media briefing on CLL, Prof John Seymour answered questions about ABT-199 CLL clinical trial deaths due to tumor lysis syndrome

December 8, 2013
E
ASH 2013 Letai

ASH 2013 BH3 profiling identifies new targets for Bcl-2 inhibitors

ABT-199 has activity in CLL, but what about other tumor types? Check out this post to find out about a new target with potential.

December 8, 2013
E
ASH 2013 Susan O'Brien CLL CME

ASH 2013 New Horizons in CLL – notes from the road

With many new therapies emerging for the treatment of CLL, what criteria can physicians use to decide which therapy to give a patient?

December 7, 2013
E
ASH Seattle Genetics Balloons

ASH 2013 Preview: quick note on non-Hodgkin’s and Hodgkin’s lymphomas

Will the B cell signaling drugs work in NHL as well as CLL? What of Adcetris in front-line HL?

December 6, 2013
E
Brentjens CART Slide

ASH 2013 Preview: will new Seattle startup Juno Therapeutics push Novartis and U Penn in CART?

Chimeric Antigen Receptor T cell technology (CART) is an exciting new area, especially in hematologic malignancies. With the formation of a new start-up in Seattle, Juno Therapeutics, things just got very interesting...

December 4, 2013
E
Sunset Miami Beach

ASH 2013 Preview – Chronic Lymphocytic Leukemia (CLL)

A review of the upcoming CLL data from the American Society of Hematology ASH meeting.

December 2, 2013
E
myeloid cells, Source: Wikipedia

ASH 2013 Multiple Myeloma Preview

Comprehensive preview of the new developments in multiple myeloma from ASH 2013.

November 25, 2013
E
ASH 2012 Atlanta meeting

ASH 2013 Myelofibrosis Preview

A lot of companies are presenting myelofibrosis data at this year's ASH annual meeting in New Orleans. This preview discusses abstracts for ruxolitinib, INCB039110, momelotinib, fedratinib, BMS-91143, pacritinib, LY2784544, pomalidomide, sonidegib.

November 11, 2013
E
aacr molecular targets boston 2013

The future of cancer research – Part 2

The huge wealth of research at the AACR-NCI-EORTC Boston conference provided a great learning environment of where future research with TKIs is likely to be heading...

November 6, 2013
E
Iwakuni Bridge

The future of cancer research – what I learned from the AACR Targets meeting Part 1

The cancer landscape is rapidly changing, in more ways than people realise. Diagnostics are also of increasing importance in helping to decide which therapies patients should receive to optimize treatment.

November 5, 2013
E
Dr Deepak Sampath, Genentech

Gazyva and ABT-199 in CLL & NHL – an interview with Genentech’s Deepak Sampath

An interview with Dr Deepak Sampath from Genentech on the rational for combining obinutuzumab (GA101) with GDC-0199 (ABT-199) for the treatment of B-cell hematological malignancies such as CLL & non Hodgkin’s lymphoma (NHL).

November 1, 2013
E
Sydney Opera House Harbor Bridge

AstraZeneca leaps over Clovis with AZD9291 data at World Lung Conference

Data presented at the World Lung Cancer conference in Sydney suggests AstraZeneca AZD9291 is now ahead of Clovis Oncology CO-1686 in the race to bring a third-generation epidermal growth factor receptor (EGFR) inhibitor to market that targets the T790M resistance mutation.

October 30, 2013
E
Fall Colors Boston

New insights on checkpoint inhibitors and CART in CLL and solid tumors

An update on checkpoint inhibitors and CART from the AACR-NCI-EORTC Molecular Targets meeting - a lot of exciting possibilities are emerging!

October 25, 2013
E
Fall Boston Colors

Abraxane kills potential of MLN0264 in pancreatic cancer

Following the FDA approval of Abraxane, MLN0264, a novel ADC targeting GCC, may no longer have potential as a therapeutic in pancreatic cancer.

October 21, 2013
E
Boston Prudential Center

Cerulean CRLX101 Challenges and Opportunities

Cerulean are developing a novel nanopharmaceutical that targets HIF1-alpha and is synergistic with anti-angiogenic drugs for RCC and Ovarian cancers.

October 21, 2013
E
Charles River Boston October 2013

AstraZeneca ramps up AZD9291 lung cancer clinical development

At the AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics conference, Susan Galbraith, M.D, Ph.D. Head of the Oncology Innovative Medicines Unit at AstraZeneca discussed the rapid development of AZD9291, a potent and selective third-generation EGFR inhibitor.

October 20, 2013
E
Boston Charles River October 2013

Pfizer next gen ALK inhibitor PF-06463922 could replace Xalkori

Preclinical data for PF-06463922 (Pfizer), a next generation ALK inhibitor, with potency for all known Crizotinib ALK resistant mutants and ability to cross the blood brain barrier was presented today at the 2013 International Conference on Molecular Targets and Cancer Therapeutics in Boston.

October 20, 2013
E
MIT Koch

A quick preview of the AACR Molecular Targets Conference

Preview of some of the interesting non-embargoed abstracts from the ACCR-NCI-EORTC Molecular Targets conference in Boston

October 15, 2013
E
Back Bay Boston

Preview of 2013 AACR Molecular Targets Conference in Boston

Preview of 2013 AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference in Boston. This is a "must attend" meeting for anyone interested in cancer drug development.

October 11, 2013
E
IMG_8574

ECCO Day 3: Update on alectinib, PD-L1, PI3K and MEK

Update on ALK (alectinib), PD-L1 (MEDI4736), PI3K (GDC-0980 and BKM120) and MEK (trametinib) inhibitors in solid tumours

September 30, 2013
E
ECCO 2013 Poster Hall

Dr Oliver Sartor shares his thoughts on Prostate Cancer data at ECCO 2013

Dr Oliver Sartor, one of the leading experts in Prostate Cancer shares his thoughts on the prostate cancer data presented at ECCO 2013.

September 30, 2013
E
BMN 673 waterfall plot in BRCA1/2 breast cancer

ECCO Highlights Day 2: Breast and Ovarian Cancer

The latest data on BioMarin's PARP inhibitor BMN 673 in breast and ovarian cancer from ECCO 2013

September 29, 2013
E
ECCO 2013 Bikes

ECCO 2013: AZD9291 shows early promise in T790M NSCLC

Promising preliminary phase 1 data for AstraZeneca’s AZD9291 in T790M+ NSCLC presented today at the European Cancer Congress (ECCO 2013) is good news for lung cancer patients.

September 29, 2013
E
ECCO 2013 Amsterdam

ECCO 2013: Is ODM-201 too late to the prostate cancer party?

At ECCO 2013 in Amsterdam, positive data was presented from the phase 1/2 clinical trial for ODM-201 (Orion) a second generation AR antagonist. In contrast the data for ASP9521 (Astellas), a novel androgen biosynthesis inhibitor was negative.

September 29, 2013
E
Source: Ariad

ECCO 2013 Notes from the Road – Day 1

Update on ipilimumab, AP26113, T-DM1, everolimus and others from Day 1 at the 2013 ECCO meeting in Amsterdam.

September 28, 2013
E
photo credit: Claudio.Ar via photopin cc

Preview of key ALK lung cancer abstracts at ECCO 2013

Review of the key abstracts in EML4-ALK lung cancer abstracts being presented at ECCO 2013 in Amsterdam.

September 23, 2013
E
ECCO 2013 Conference Amsterdam

A top line look at the PD-1 and PD-L1 abstracts at ECCO 2013

A quick review of the check point immunotherapy abstracts from #ECC2013 in Amsterdam.

September 19, 2013
E
Tulips

Preview of 2013 European Cancer Congress in Amsterdam

2013 European Cancer Congress organized by ECCO takes place in Amsterdam from September 27 to October 1st. This is a preview of some of the abstracts to watch out for at the meeting.

September 16, 2013
E
Video Interview with Dr Susan O'Brien

ASCO 2013 Video Interview with Dr Susan O’Brien on CLL new drugs in development

It's exciting times in Chronic Lymphocytic Leukemia (CLL) with a lot of new data expected at the forthcoming 2013 annual meeting of the American Society of Hematology (#ASH13) in New Orleans. At ASCO 2013, Dr Susan O'Brien shared her thoughts on several new CLL drugs in development including ABT-199, ibrutinib, idelalisib, AV-292, obinutuzumab and IP-145.

June 10, 2013
E
ASCO 2013 Celgene Pancreatic Cancer Sign

ASCO 2013 Abraxane in pancreatic cancer is a welcome new treatment option

At ASCO 2013 the phase III MPACT trial data for Abraxane in pancreatic cancer was presented. This data was first reported at ASCO GI earlier this year. Abraxane in pancreatic cancer is a welcome new treatment option but it is not a major breakthrough that offers a dramatic shift in outcome.

June 7, 2013
E
ASCO 2013 Chicago Skyline

AZD3514 Fails to Live up to Preclinical Promise in CRPC at ASCO 2013

The novel SARD inhibitor AZD3514 showed preclinical promise in advanced prostate cancer, but the phase 1 first-in-human clinical trial showed it had tolerability problems, and it's development in CRPC has been terminated by AstraZeneca.

June 6, 2013
E
ASCO 2013 Annual Meeting

ASCO 2013 Pfizer joins race to develop a Herceptin biosimilar with PF-05280014

At ASCO 2013, there was a lot of interest in a poster on Pfizer's PF-05280014, a potential biosimilar to Herceptin.

June 5, 2013
E
ASCO 2013 Charles Sawyers Science of Cancer Award

ASCO 2013: Cancer Drug Combinations are The Future

At ASCO 2013 Dr Charles Sawyers received the 2013 Science of Oncology Award, after which he gave an insightful lecture on Overcoming Resistance to Cancer Drug Therapy. His message was clear that combinations of cancer drugs are the future.

June 3, 2013
E
ASCO 2013 CLL New Treatments

ASCO 2013 CLL Runners and Riders in Race to Market #ASCO13

New clinical data on ibrutinib, obinutuzumab, idelalisib, IPI-145, ABT-199 for the treatment of Chronic Lymphocytic Leukemia (CLL) will be presented at ASCO 2013.

May 28, 2013
E
ASCO-2013-Preview-Video

ASCO 2013 Preview Video

ASCO 2013 Preview Video of what's hot at the meeting for cancer new products in immunotherapy, CLL, breast cancer, lung cancer and breast cancer. Includes a MOA of PD-L1.

May 28, 2013
E
AACR 2013 Annual Meeting Washington DC

AACR 2013 Posters offer Insights into Biotech Drug Development

The poster sessions at the 2013 annual meeting of the American Association for Cancer Research (AACR) are not all about mice, and test tubes, but offer insights into biotech drug development, new targets and licensing opportunities.

April 15, 2013
E
White House Washington DC

AACR 2013 posters show potential new Pfizer cancer drugs

My overriding impression of large cap Pharma R&D from the 2013 annual meeting of the American Association for Cancer Research (AACR) was that Novartis and Genentech remain the front-runners in cancer drug development, with Pfizer very much up and coming.

April 12, 2013
E
Power of Social Media

AACR 2013 Cancer Scientists fail to embrace Social Media

Cancer scientists have not embraced social media in the way cancer doctors and patient advocates have. To support public funding of research, cancer scientists need to communicate the value of the scientific research they conduct. One way to do this is to embrace social media more, particularly at meetings such as AACR, where there is the opportunity to share information with a worldwide audience.

April 11, 2013
E
AACR 2013 Annual Meeting

AACR 2013 GDC-0032 a next generation PI3K Inhibitor shows early promise in breast cancer

GDC-0032 is a next generation PI3K inhibitor that spares the beta-isoform of PI3K. Genentech hypothesize this may reduce some of the undesired side effects such as effects on metabolism, previously seen with pan PI3K inhibitors such as GDC-0941. At AACR 2013 promising early clinical data was presented for GDC-0032 in PI3KCA mutant cancers, especially breast cancer.

April 8, 2013
E
Washington Monument Cherry Blossom

AACR 2013 DMUC5754A is a novel agent for Ovarian Cancer

AACR 2013: A late-breaking clinical trial presentation to watch is LB-290: Targeting MUC16 with the Antibody-Drug Conjugate DMUC5754A in patients with platinum-resistant ovarian cancer. This data will be presented by Joyce Liu, MD, MPH from Dana-Farber Cancer Institute in the Clinical Trials Symposium on Tuesday, Apr 9 at 4.00 pm.

April 7, 2013